"Sodium Oxybate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The sodium salt of 4-hydroxybutyric acid. It is used for both induction and maintenance of ANESTHESIA.
| Descriptor ID |
D012978
|
| MeSH Number(s) |
D02.241.081.114.937.700 D02.241.511.429.700
|
| Concept/Terms |
Sodium Oxybate- Sodium Oxybate
- Oxybate, Sodium
- Sodium Oxybutyrate
- Oxybutyrate, Sodium
- Sodium gamma-Hydroxybutyrate
- Sodium gamma Hydroxybutyrate
- 4-Hydroxybutyrate Sodium
- 4 Hydroxybutyrate Sodium
- Oxybate Sodium
|
Below are MeSH descriptors whose meaning is more general than "Sodium Oxybate".
Below are MeSH descriptors whose meaning is more specific than "Sodium Oxybate".
This graph shows the total number of publications written about "Sodium Oxybate" by people in this website by year, and whether "Sodium Oxybate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sodium Oxybate" by people in Profiles.
-
Randomized, crossover, open-label study of the relative bioavailability and safety of FT218, a once-nightly sodium oxybate formulation: Phase 1 study in healthy volunteers. Sleep Med. 2022 Dec; 100:442-447.
-
Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications. CNS Drugs. 2022 06; 36(6):633-647.
-
Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON Trial. CNS Drugs. 2022 04; 36(4):377-387.
-
Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study. Lancet Neurol. 2022 01; 21(1):53-65.
-
Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy. Sleep. 2021 03 12; 44(3).
-
Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications. Sleep Med. 2020 04; 68:97-109.
-
Impact of sodium oxybate, modafinil, and combination treatment on excessive daytime sleepiness in patients who have narcolepsy with or without cataplexy. Sleep Med. 2016 08; 24:57-62.
-
Time to response with sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy. J Clin Sleep Med. 2015 Apr 15; 11(4):427-32.
-
Weight loss in narcolepsy patients treated with sodium oxybate. Sleep Med. 2009 Jun; 10(6):661-3.
-
Permanent neurologic damage from chronic gamma hydroxybutyrate abuse. Am J Addict. 2006 Nov-Dec; 15(6):483-4.